Kiora Pharmaceuticals
KPRX
19 hedge funds and large institutions have $1.39M invested in Kiora Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
12% more funds holding
Funds holding: 17 → 19 (+2)
1.28% more ownership
Funds ownership: 17.95% → 19.22% (+1.3%)
19% less capital invested
Capital invested by funds: $1.71M → $1.39M (-$322K)
Top Buyers
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$175K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
+$167K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.8K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$27.3K |
| 5 |
Renaissance Technologies
New York
|
+$20.1K |
Top Sellers
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$115K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$50.6K |
| 3 |
Two Sigma Investments
New York
|
-$33.3K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$21.6K |
| 5 |
Citigroup
New York
|
-$10.9K |
KPRX Hedge Fund Activity: Q4 2025 in Review
19 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q4 2025, worth a combined $1.39M — down 19% from $1.71M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new KPRX positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $175K. The largest seller was Nantahala Capital Management, cutting an estimated $115K.
- 19 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q4 2025, up from 17 in Q3 2025.
- Funds reported $1.39M of Kiora Pharmaceuticals stock for Q4 2025, down 19% quarter-over-quarter.
- 4 funds opened new Kiora Pharmaceuticals positions in Q4 2025 and 2 closed out, a net change of +2 holders.
- The largest Kiora Pharmaceuticals buyer in Q4 2025 was Alyeska Investment Group, an estimated $175K added.
- The largest Kiora Pharmaceuticals seller in Q4 2025 was Nantahala Capital Management, an estimated $115K sold.
Based on aggregated 13F filings for Q4 2025.